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Abstract: Objective 
The present study aimed at estimating the prevalence of metabolic syndrome (MetS) and 
prospectively, evaluating cardiovascular events among Asian Indians type 2 diabetic subjects. 
Methods 
The sample comprised of 1522 type 2 diabetic mellitus (T2DM) subjects aged 25 -91 years, who 
participated in the North Indian Diabetes and cardiovascular Disease Study (2011-2014). The 
participants were screened for hypertension, dyslipidemia, obesity and cardiovascular events. 
Anthropometric, clinical and biochemical measurements were done in all subjects. The prevalence of 
MetS was estimated in all the subjects according to the harmonized criteria of 2009. 
Results 
The prevalence of MetS among urban Indian diabetic subjects was 71.9% and was significantly higher 
in females (86%) as compared to males (57.9%). To determine the independent predictors of the MetS 
in diabetic sample, binary logistic regression analyses were performed using demographic and 
biochemical parameters. Significant differences in the indices of generalized and abdominal obesity 
and lipids (Total cholesterol, High Density Lipoprotein) were observed (p < 0.01) in male: female and 
MetS and non-MetS comparisons. Regression analysis for prediction of CVD showed that family history, 
age, Body Mass Index (BMI), SBP, physical inactivity and hypertension independently and significantly 
predicted the disease outcome. Binary logistic regression analysis for prediction of CVD risk was found 
to be an independent risk/predictor (Odd Ratio (OR) =3.44, CI 1.31-9.01) along with higher age groups, 
BMI and hypertension.  
Conclusion 
The study demonstrated the high prevalence of MetS and its different components were positively 
associated with a higher risk of cardiovascular disease in north Indian diabetic subjects. Nevertheless, 
MetS is a major health problem in India, comprehensive population studies are warranted for 
estimation of incidence and prevalence, and education should be provided on its prevention and 
control to reduce the diabetes-related morbidity and mortality. 
 
 
 
Highlights (for review) 
1. The present study demonstrated a high prevalence of metabolic syndrome in an urban 
Indian diabetic population.  
2. The prevalence of MS among urban Indian diabetic patients was 69.6% and was 
significantly higher in females (86%) as compared to males (57.9%).  
3. Significantly differences in the indices of generalized and abdominal obesity (BMI, 
waist, WHR) and lipids (Total cholesterol, HDL-cholesterol) were observed in male: 
female and MS and non-MS comparisons.  
4. Regression analysis for prediction of CHD showed that family history, age group 
classification, BMI, SBP, physical activity and hypertension independently and 
significantly predicted the disease outcome.  
5. Binary logistic regression analysis for prediction of CHD risks was found to be an 
independent risk/predictor (OR=3.44, CI 1.31-9.01) along with higher age groups, BMI 
and hypertension.  
Highlights (for review)
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ABSTRACT 
Objective 
The present study aimed at estimating the prevalence of metabolic syndrome (MetS) and 
prospectively, evaluating cardiovascular events among Asian Indians type 2 diabetic subjects. 
Methods 
The sample comprised of 1522 type 2 diabetic mellitus (T2DM) subjects aged 25 -91 years, who 
participated in the North Indian Diabetes and cardiovascular Disease Study (2011-2014). The 
participants were screened for hypertension, dyslipidemia, obesity and cardiovascular events. 
Anthropometric, clinical and biochemical measurements were done in all subjects. The prevalence 
of MetS was estimated in all the subjects according to the harmonized criteria of 2009. 
Results 
The prevalence of MetS among urban Indian diabetic subjects was 71.9% and was significantly 
higher in females (86%) as compared to males (57.9%). To determine the independent predictors 
of the MetS in diabetic sample, binary logistic regression analyses were performed using 
demographic and biochemical parameters. Significant differences in the indices of generalized and 
abdominal obesity and lipids (Total cholesterol, High Density Lipoprotein) were observed (p < 
0.01) in male: female and MetS and non-MetS comparisons. Regression analysis for prediction of 
CVD showed that family history, age, Body Mass Index (BMI), SBP, physical inactivity and 
hypertension independently and significantly predicted the disease outcome. Binary logistic 
regression analysis for prediction of CVD risk was found to be an independent risk/predictor (Odd 
Ratio (OR) =3.44, CI 1.31-9.01) along with higher age groups, BMI and hypertension.  
Conclusion 
The study demonstrated the high prevalence of MetS and its different components were positively 
associated with a higher risk of cardiovascular disease in north Indian diabetic subjects. 
Nevertheless, MetS is a major health problem in India, comprehensive population studies are 
warranted for estimation of incidence and prevalence, and education should be provided on its 
prevention and control to reduce the diabetes-related morbidity and mortality. 
Key Words 
Metabolic syndrome, Harmonized criteria of metabolic syndrome, Type 2 diabetes, cardiovascular 
disease, Asian Indians. 
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1  Introduction 
India is witnessing a depressing situation due to escalating incidence and prevalence of type 2 
diabetes mellitus (T2DM) and its inevitable outcomes of cardiovascular diseases (CVD), diabetic 
neuropathy, nephropathy and retinopathy (Anjana et al., 2011; Mohan et al., 2010; Ramachandran 
et al., 1997). Recent estimates revealed that India currently has more than 65 million people with 
type 2 diabetes and this numbers is predicted to be doubled in next 20 years (Guariguata et al., 
2014). Metabolic syndrome (MetS) is a constellation of metabolic risk factors comprising 
abdominal obesity, glucose intolerance, hyperinsulinaemia, hypertension and dyslipidemia 
characterized by low levels of HDL-cholesterol and elevated levels of triglycerides (Reaven, 
1988). MetS has been reported as a risk factor for cardiovascular disease and mortality (Isomaa et 
al., 2001; Lakka et al., 2002). There was no internationally agreed criterion of defining MetS 
resulting variation in the global prevalence of MetS using different criteria. Recently, a joint 
scientific statement by various health organizations proposed to unify the diagnostic criteria of 
metabolic syndrome with population and country specific waist circumferences (Alberti et al., 
2009). Both diabetes and CVD are consequences of the insulin resistance syndrome, also known as 
the metabolic syndrome (Meigs, 2010; Wilson et al., 2005). Each component of the cluster 
conveys increased risk of CVD, but as a combination they become much more powerful. Despite 
its high prevalence, little is known of the prospective association of the metabolic syndrome with 
cardiovascular and overall mortality. A very few systematic studies on the prevalence of MetS 
have been reported from the Indian subcontinent (Ramachandran et al., 2003). The present study 
was planned to estimate the prevalence of MetS in T2DM subjects according to the harmonized 
criteria of metabolic syndrome (2009) and evaluate the risk of cardiovascular events in urban 
Asian Indian population. 
2  Material and Methods 
2.1 Human Subjects: The present study included 1522 diabetic individuals (887 males and 635 
females). The North Indian Diabetes and Cardiovascular Disease Research (NIDCVD) study was 
planned in 2011 with the aim of investigating the interplay of genetic and environmental factors 
associated with high prevalence of T2DM and cardiovascular diseases in Indian population (Bhatti et 
al., 2014). The T2DM subjects were diagnosed as per the criteria established by American Diabetes 
Association (American Diabetes Association, 2004) i.e. a medical record of either a fasting plasma 
glucose (FPG) levels ≥7.0 mmol/l or ≥126 mg/dl after a minimum 12-hour fast or 2-hour post 
glucose level (oral glucose tolerance test or 2-h OGTT) ≥11.1 mmol/l or ≥200 mg/dl on more than 
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one occasion with symptoms of diabetes. The impaired glucose tolerance (IGT) was defined as the 
FPG levels 100 mg/dl (5.6 mmol/l) but <126 mg/dl (7.0 mmol/l) or 2-h OGTT of ≥140 mg/dl (7.8 
mmol/l) but <200 mg/dl (11.1 mmol/l). The diagnosis of T2DM was based on clinical and medical 
records of the participant. In the absence of medical record information, we confirmed a self-
reported T2DM case by establishing that there is regular treatment with hypoglycemic medication or 
by testing the self-reported T2DM cases by performing 2-h OGTT. Informed written consent was 
obtained from all individual participants included in the study. This study was ethically approved by 
Institutional Ethics Committee of Post Graduate Institute of Medical Education and Research, 
Chandigarh, India.  
2.2 Definition of Metabolic Syndrome  
Metabolic Syndrome was defined according to the recent harmonized criteria (Alberti et al., 2009). 
The definition of MetS included five components: (1) central obesity (waist circumference ≥ 90 cm 
for Asian Indian men and ≥ 80 cm for Asian Indian women; (2) elevated blood pressure: systolic ≥ 
130 mmHg, diastolic ≥ 85 mmHg, or known treatment for hypertension; (3) elevated triglycerides: 
fasting plasma triglycerides ≥ 150 mg/dL (1.7 mmol/L), drug treatment for elevated triglycerides is 
an alternate indicator; (4) low HDL-C: fasting HDL-C < 1.0 mmol/L in men and < 1.3 mmol/L in 
women, drug treatment for reduced HDL-C is an alternate indicator; and (5) hyperglycemia: fasting 
glucose level of ≥ 5.6 mmol/L (≥ 100 mg/dL) or known treatment for diabetes, drug treatment of 
elevated glucose is an alternate indicator. MetS was positive if an individual had at least three 
positive of these 5 components. All patients previously diagnosed with and were receiving 
medications for hypertension, diabetes or dyslipidemia were included in the study and were 
deliberated as having these risk factors.  
2.3 Inclusion/ Exclusion criteria: Male and female volunteer T2DM, participants aged>25 years, 
belonging to north Indian states (Punjab, Haryana, Himachal Pradesh, Delhi and J&K) were 
included. The individuals belonging to South, East and Central Indian origin, type-I diabetes 
(T1DM) or family member with T1DM, rare form of T2DM sub-type were excluded.  
2.4 Anthropometric measurements 
Standard anthropometric measurements were performed including height, weight, waist and hip 
circumferences and blood pressure. Waist and Hip circumference was measured with a metal tape 
using standard procedures. Height was measured with a stature meter and weight with a portable 
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balance beam scale. Blood pressure was measured by Omron blood pressure machine in sitting 
position from the left arm resting on the table, with legs uncrossed and feet flat. Direct physical 
examination was performed to evaluate the severity and progression of diabetes-related 
complications reported in patient’s medical records.  
2.5 Biochemical measurements: 
Blood samples were drawn in plain and EDTA coated vials. Fasting and random blood glucose 
levels were measured using a portable glucometer (OptiumXceed, Abbott Diabetes Care Inc. 
USA). Calibration of the glucometer was routinely verified using test strips provided by the 
manufacturers. Serum was used for quantization of lipid profile [total cholesterol (TC), 
triglycerides (TG), high density lipoprotein (HDL) cholesterol, and creatinine levels. Low density 
lipoprotein (LDL) level was calculated by using Friedewald formula i.e. LDL-C = TC – [HDL-C – 
(TG in mg/dl/5)]. All the quantitative parameters were measured by following manufacturer’s 
instructions using biochemistry autoanalyzer.  
2.6 Phenotypic Evaluation of Study Subjects 
Information regarding age at the time of diagnosis, Coronary Heart Disease or stroke, coronary 
artery bypass graft (CABG) or angioplasty, and medication was obtained from patient records. 
Cardiovascular disease (CVD) was diagnosed based on a history of documented myocardial 
infarction and/or drug treatment for CVD (aspirin or nitrates). Hypertension was defined as a self-
reported history of a systolic blood pressure (SBP) of >140 mm Hg and/or diastolic blood pressure 
(DBP) of >90 mm Hg or subjects who were receiving drug treatment for hypertension. Ocular 
complications were recorded based on medical records. Neuropathy was documented as tingling or 
burning of fingers or toes, numbness, or diminished sensation at lower extremities and /or sharp 
pains or cramps, sexual dysfunction, uncontrolled urinations, perfused sweating at night or while 
eating, and hearing loss. 
2.7 Derived Measures  
Quantitative measures of obesity include the body mass index (BMI), waist-to-hip ratio (WHR) 
and per cent body fat. BMI was calculated according to Quetelet equation i.e. (BMI = weight in 
kilograms/height in meters squared). WHR was calculated as ratio of abdomen to hip 
circumferences.  
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Body fat percentage (BF%) was calculated using following formulae (Lean et al., 2001): 
BF% for men = [(0.567 × waist circumference in cm) + (0.101 × age in years)] − 31.8; and 
BF% for women = [(0.438 × waist circumference in cm) + (0.221 × age in years)] − 9.4. 
World Health Organization recommended BMI threshold values for Asian populations 
(Consultation, 2004) are:  a) <23 kg/m2 for low risk, b) 23–27.5 kg/m2 for increased risk, and c) 
>27.5 kg/m2 for high risk. 
Abdominal obesity was measured according to the cut-off values for normal anthropometric 
variables proposed for South Asians i.e. WHR <0.89 for men and <0.81 for women (Snehalatha et 
al., 2003). 
2.8 Statistical Analysis 
Continuous and categorical variables were analysed by unpaired t-tests and χ2-square test 
respectively.  Comparisons between males and females and MetS and Non-MetS categories were 
carried out using IBM-SPSS for Windows, version 19 (SPSS, Inc., Chicago, IL). All the p-values 
<0.05 (two-tailed) were considered as significant difference. Logistic regression analysis was 
carried out to correlate various clinical parameters with disease. Bonferroni corrected p-value was 
used for the assessment of significance which controlled the multiple comparisons.  
3 Results 
Of all the 1522 diabetic subjects (887 males and 635 females), 55.9% were receiving oral 
antihyperglycemic medications (OAHM), 4.1% were on insulin therapy, 19.6 % were on insulin 
therapy alongwith OAHM, 9.1% were not taking any regular medication and 11.2% were 
maintaining their glucose levels by diet and exercises only. Physical activity was low in 65.5% 
subjects, 7.3% had a sedentary lifestyle and only 27.2% are very active. Mean age of diagnosis and 
duration of diabetes was 50.8 years and 7.2 years, respectively. A positive family anamnesis of 
diabetes was documented in more than 60% of diabetic subjects. Central obesity (p<0.0001) and 
low HDL (p<0.0001) were also significantly more prevalent in women. Men were more likely to 
have hypertension (p=0.001).  
Considering the entire cohort of 1522 diabetic patients, MetS was prevalent in 72% of Asian 
Indian diabetic subjects. The MetS was more prevalent in women (86%) as compared to men 
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(57.9%), leading to statistically significant differences between the genders (chi-square =136.7, 
p<0.001). The prevalence of MetS in the study subjects by their age groups was shown in Fig. 1. 
No significant difference in the prevalence of MetS was observed in male and female subjects 
under the age group of <50 years.  However, high prevalence was observed in both males and 
females in age groups of 50-60 years (32.3% vs. 37.4%) and 60-70 years (26.3 vs 27.8%) (Fig. 2). 
Considering the 1060 diabetic patients having diagnosed with metabolic syndrome, it was found 
that 159 (15.0%) subjects were positive for all five risk factors of MetS, 372 (35.1%) subjects had 
four risk factors, and 529 (49.9%) subjects had three risk factors (Fig. 4). Metabolic risk factors 
were more prevalent in women with five components of MetS (24.2% in women vs. 5.3% in men) 
and four components of MetS (40.3% in women vs. 29.6% in men). However higher proportion of 
3 components of MetS was observed in men than women (65.2% vs. 35.5%). 
Table 1 show the anthropometric and clinical parameters of MetS and Non-MetS subjects. The 
mean age of the Non-MetS subjects was comparable to that of the MetS subjects (58.05±11.4 vs 
58.01.6±10.9, p=0.95). No significance difference in the duration of diabetes was observed in 
MetS and Non-MetS subjects.  As expected MetS subjects had higher values of BMI, waist and hip 
circumferences, WHR, SBP, DBP, glucose, cholesterol, TG, LDL, and VLDL while HDL levels 
were lower. Comparison of males and females showed statistically significant differences in a 
number of parameters for MetS category which included BMI, hip circumference, and Cholesterol 
and LDL levels.  Males in MetS category were having higher values for BMI, hip circumference, 
glucose, cholesterol and LDL. In Non-MetS category, males were having higher WHR, whereas 
females carried higher body fat, higher glucose and cholesterol (Table 1).  
Overall distribution of socioeconomic characteristics were similar in MetS and Non-MetS subjects 
and males and females diabetic subjects (Table 2). Analysis of clinical outcomes/conditions 
according to MetS criteria showed significant differences between MetS and Non-MetS diabetics 
for Hypertension in overall sample and male and female subgroups (p<0.0001) as shown in Table 
3. Women had a significantly higher prevalence of abdominal obesity (p<0.0001) and low values 
of HDL (p<0.0001), while men were significantly more likely to have hypertension (p<0.0001) 
and hypertriglyceridemia (p<0.0001).  
To determine the independent predictors of the MetS in diabetic sample, binary logistic regression 
analyses were performed using demographic and biochemical parameters and results are given in 
table 4. Regression analysis for prediction of CVD showed that family history, age, BMI, SBP, 
physical inactivity and hypertension independently and significantly predicted the disease outcome 
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(Table 5). MetS risk factors and established biochemical parameters (like Cholesterol, TG, HDL, 
LDL, VLDL) did not contribute significantly to CVD risk in this sample of diabetic individuals.  
4 Discussion 
The high prevalence of type 2 diabetes in Asian Indians poses a major health and economic burden 
to the country and reported to anguish the Asian Indians a decade earlier than the rest of the world. 
The metabolic syndrome, a cluster of altered glucose metabolism, abdominal obesity, body fat 
distribution, hypertension and dyslipidemia, is associated with consequent increase in diabetes and 
cardiovascular diseases. The prevalence of MetS in Asian Indians varies according to the region, 
the extent of urbanization, lifestyle patterns, and socioeconomic/cultural factors. Recent studies 
reported the higher prevalence of MetS in India’s major cities (Gupta et al., 2004; Manjunath et al., 
2014; Ramachandran et al., 2003; Singh et al., 2007). Since the implications of MetS for 
healthcare are substantial, it is essential to establish the prevalence of this condition among north 
Indian diabetic patients. The prevalence of MetS in the current study showed gender-specific 
differences. Findings of the present study indicate that MetS is very common with an estimated 
overall prevalence of 72% in Asian Indian diabetic subjects. Our study mirrors the observations of 
previous studies which documented a high prevalence of MetS among individuals with T2DM 
(Raman et al., 2010; Surana et al., 2008). This study provides estimates of the MetS prevalence in 
north Indian urban diabetic population which is nearly 30% higher in the females and nearly 30-
40% higher prevalence in the general urban Indian population. Because South Asians develop 
metabolic abnormalities at a lower body mass index and waist circumference than other groups, 
conventional criteria underestimate the prevalence of MetS by 25% to 50% (Enas et al., 2007). 
Systematic studies are lacking from India to estimate prevalence of MetS in this region, but overall 
trend is on increase (Agrawal et al., 2011; Gupta et al., 2004). Ramachandran et al reported a 
prevalence of 41% in urban area of Chennai using modified ATP-III criteria among adults aged 20 
to 75 years (Ramachandran et al., 2003). They also reported higher prevalence of MetS in women 
than men (46.5% vs 36.4%). Approximately 30-50% of urban South Asians have MetS (Deepa et 
al., 2007; Mohan et al., 2001). The prevalence increases to >73% in people with diabetes with 
women having even higher prevalence (83%) compared to men (65%) (Raman et al., 2010). 
Recent studies on diabetic subjects in different parts of the world reported 75.6% prevalence of 
MetS from the USA (Bruno et al., 2004) and 77% prevalence of MetS in diabetic Indian 
immigrants in the USA (Foucan et al., 2006) and 79.7% in Pakistan (Imam et al., 2007). Indian 
immigrants with T2DM had a 5-fold higher risk of MetS than the general population group. Our 
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results are similar to these studies measuring the prevalence of metabolic syndrome in diabetic 
population.  
According to the recent definition of metabolic syndrome (Alberti et al., 2009) with recommended 
waist circumference for Asian Indians, the risk of MetS was increased in women, subjects with 
elevated glucose levels, dyslipidemia and hypertension. As expected, there were significant 
differences between males and females and MetS and non-MetS subjects for a range of 
demographic and clinical parameters. These values were highly significant even after the 
Bonferroni correction for multiple comparisons. Waist circumference, hypertension and 
hyperglycemia contributed as independent predictors of MetS in this population using regression 
analysis. The highest odds ratio was observed for presence of hypertension (OR =35.95, CI=20.98-
61.58), suggesting that hypertension is highly prevalent in this region and specific treatment and 
lifestyle interventions may be required.  
It is well known that cardiovascular morbidity and mortality is associated with the individual 
components of metabolic syndrome (Isomaa et al., 2001). We tested this using regression analysis 
for prediction of CVD risks, central obesity was found to be an independent risk/predictor along 
with higher age categories, BMI and hypertension. Currently available evidence suggests that 
MetS is associated with significantly increased risk of incident cardiovascular disease, all-cause 
and cardiovascular death (Ford, 2005; Galassi et al., 2006; Mottillo et al., 2010). A previous study 
demonstrated that in diabetic patients, the presence of metabolic syndrome is associated with a 5-
fold increase in CVD risk independent of age, sex, smoking status, and glycosylated haemoglobin 
(Bonora et al., 2004). The analysis also showed that higher physical activity, lower SBP, lower 
weight protects against development of the CVD. This is consistent with other studies which 
suggest MetS increases risk of cardiovascular diseases (Gami et al., 2007). Previous studies also 
reported that the increasing rates of obesity are associated with increasing rates of diabetes, which 
in turn are associated with increasing rates of CVD in the Framingham Heart Study (Meigs, 2010). 
The link between MetS and increased CVD risk has also reported in many large scale clinical 
intervention trials in western populations (Bonora et al., 2004; Girman et al., 2004; Sattar et al., 
2003). Studies from Indian subcontinent are limited. In our analysis, it is clear that MetS 
individuals have three fold increased risk of CVD compared to non-MetS individuals. A study in a 
Italian elderly population had shown, among MetS components, all-cause mortality is better 
predicted by IFG in all subjects and in women, and by low HDL-C in women; whereas CVD 
mortality is better predicted by IFG and low HDL-C in women (Zambon et al., 2009) . Although 
10 
 
dyslipidemia was more prevalent in MetS subjects of this study, one interesting aspect of this 
analysis is the lack of significance for lipid parameters in the development of CVD in this 
population. This may be because of the regular use of the lipid lowering drugs used by >80% of 
the CVD and hypertensive patients of this study. Previous studies have shown the reduction in 
cardiovascular morbidity and mortality in diabetic patients with statin therapy (Sheng et al., 2012). 
A combination of hypertriglyceridemia, low levels of HDL-cholesterol and high levels of small 
dense low-density lipoprotein is particularly seen in Asian Indians (Misra et al., 2004). 
Furthermore, Asian Indians have at least double the risk of CVD than that of whites, even when 
adjusted for the presence of diabetes and MetS (Enas et al., 2007). This again indicates that South 
Asian/Asiatic Indians have different risk factors for development of CVD. This study was the first 
study in north India that has evaluated the prevalence of MetS in type 2 diabetic subjects. Our 
study has some limitations also that must be accounted for when interpreting our findings. This 
was a cross-sectional research study conducted in a research institute with targeted recruitment of 
patients and controls. Therefore, whether our findings reflect those from a broader population with 
diabetes at the community or primary care level is not known. However this should not affect any 
interpretations of MetS prevalence and its contributing factors or its effect on the development of 
CVD.  
In conclusion, our analyses show that MetS is highly prevalent in this north Indian urban diabetic 
population. It is clear from our analyses, MetS, as defined by the modified NCEP/ATP-III criteria, 
appears to almost triple the risk of CVD in this population. This is not surprising since metabolic 
syndrome contains well-established cardiovascular risk factors such as hypertension and 
dyslipidemia.  Hypertension seems to be the most significant risk factor for both MetS and CVD in 
this population which may require targeted therapeutic and lifestyle interventions to reduce the 
disease burden in this region. In addition healthcare professionals must support patients with MetS 
in prevention or delaying progression to diabetes, cardiovascular disease, and other related 
complications. This study despite its limitations contributes to mapping the prevalence of MetS 
worldwide, particularly with regards to people with diabetes in North India. 
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Figure Legends 
Fig 1. Distribution of study subjects by age. 
Fig 2. Prevalence of MS in diabetic subjects by Age and Sex. 
Fig. 3 : Proportion of metabolic risk factors in patients with metabolic syndrome. 
  
Table
Table 1. Demographic and clinical characteristics according to modified NCEP ATP III criteria of MetS among Asian Indian 
Diabetic Subjects  
Parameter 
 
Men Women p-Value  
Male vs. 
Female  
Total  
N Mean±SD p- value N Mean±SD p- value N Mean±SD p- value 
Age (Years) Non-MetS 373 58.79±11.76 0.64 89 54.97±10.99 0.35 0.006 462 58.05±11.70 0.95 
MetS 514 58.42±11.36 546 57.63±10.42 0.23 1060 58.01±10.89 
BMI (kg/m
2
) Non-MetS 373 25.08±3.81 <0.0001 89 25.63±4.77 <0.0001 0.25 462 25.19±4.01 <0.0001 
MetS 514 26.70±4.15 546 27.99±4.91 <0.0001 1060 27.36±4.60 
Waist (inch) Non-MetS 373 36.36±3.01 <0.0001 89 34.63±3.87 <0.0001 <0.0001 462 36.03±3.26 <0.0001 
MetS 514 38.26±4.24 546 38.03±4.38 0.39 1060 38.14±4.31 
Hip (inch) Non-MetS 373 37.39±2.87 <0.0001 89 37.69±4.08 <0.0001 0.42 462 37.45±3.13 <0.0001 
MetS 514 38.67±3.43 546 39.72±4.34 <0.0001 1060 39.21±3.96 
WHR Non-MetS 373 0.97±0.05 <0.0001 89 0.92±0.06 0.01 <0.0001 462 0.96±0.06 0.075 
MetS 514 0.99±0.06 546 0.98±0.48 0.47 1060 0.98±0.35 
Systolic BP Non-MetS 373 141.54±20.52 <0.0001 88 136.08±21.26 <0.0001 0.03 461 140.50±20.75 <0.0001 
MetS 514 148.12±26.19 546 146.19±22.35 0.64 1060 147.13±24.30 
Diastolic BP Non-MetS 373 82.61±10.95 <0.0001 88 80.93±8.86 0.007 0.18 461 82.29±10.59 <0.0001 
MetS 514 85.55±12.38 546 83.91±12.38 0.19 1060 84.71±12.40 
Bodyfat % Non-MetS 373 26.50±4.38 <0.0001 89 41.22±4.73 <0.0001 <0.0001 462 29.34±7.32 <0.0001 
MetS 514 29.20±6.15 546 45.59±5.37 <0.0001 1060 37.64±10.01 
Glucose 
(mg/dL) 
Non-MetS 358 164.64±64.03 0.92 82 173.98±70.00 0.64 0.24 440 166.38±65.20 0.74 
MetS 499 165.05±61.12 520 170.09±73.69 0.12 1019 167.63±67.84 
Cholesterol 
(mg/dL) 
Non-MetS 294 171.89±43.07 <0.0001 46 183.83±38.91 0.34 0.08 340 173.50±42.68 <0.0001 
MetS 501 183.81±48.66 502 189.73±51.35 <0.0001 1003 186.77±50.08 
Triglycerides 
(mg/dL) 
Non-MetS 294 136.13±72.64 <0.0001 46 125.07±37.25 <0.0001 0.31 340 134.63±68.98 <0.0001 
MetS 501 206.04±110.62 502 177.48±86.31 0.17 1003 191.74±100.18 
HDL (mg/dL) Non-MetS 294 42.41±8.07 <0.0001 46 46.93±12.36 <0.0001 0.001 340 43.02±8.89 <0.0001 
MetS 501 37.09±8.55 502 39.05±8.68 0.19 1003 38.07±8.67 
LDL (mg/dL) Non-MetS 294 102.27±39.42 0.28 46 111.89±37.26 0.57 0.12 340 103.57±39.22 0.008 
MetS 501 105.52±44.31 502 115.19±45.78 <0.0001 1003 110.36±45.29 
VLDL 
(mg/dL) 
Non-MetS 294 27.22±14.53 <0.0001 46 25.01±7.45 <0.0001 0.31 340 26.92±13.80 <0.0001 
MetS 501 41.21±22.12 502 35.49±17.26 0.17 1003 38.35±20.04 
Creatinine 
(mg/dL) 
Non-MetS 288 0.91±1.08 0.9 46 0.88±0.58 0.15 0.18 334 0.91±1.02 0.25 
MetS 480 0.93±1.39 484 0.74±0.89 0.004 964 0.83±1.17 
Data values written as mean ± SD. BP, Blood Pressure; TG, Triglycerides; WC, Waist Circumference; BMI, Body Mass Index; HDL, 
High Density Lipoprotein; LDL, Low Density Lipoprotein; VLDL, Very Low Density Lipoprotein
Table 2. Socioeconomic Characteristics of MetS and Non-MetS Subjects among Asian Indian 
Diabetic Subjects. 
Characteristic Male Female Total 
Non-
MetS 
MetS p Non-
MetS 
MetS p Non-
MetS 
MetS p 
Education Total No. 372 513  
 
 
 
 
0.96 
89 544  
 
 
 
 
0.42 
461 1057  
 
 
 
 
0.11 
Illiterate  5.6% 5.4% 11.2% 16.4% 6.7% 11.1% 
Primary 24.5% 22.8% 37.1% 31.4% 26.9% 27.2% 
Secondary 28.8% 28.3% 24.7% 23.5% 27.9% 25.8% 
Diploma 5.9% 6.0% 1.1% 4.0% 4.9% 5.0% 
Degree 35.2% 37.4% 25.4% 24.6% 33.4% 30.8% 
Economic 
Status/ 
Job grade 
Total No. 372 512  
 
 
0.01 
89 544  
 
 
0.81 
461 1056  
 
 
0.13 
Low income 10.0% 17.8% 6.4% 6.4% 9.1% 11.9% 
Middle income 76.6% 72.1% 87.6% 84.6% 78.8% 78.5% 
High income 13.4% 10.1% 6.7% 9.0% 12.1% 9.6% 
Physical 
activity 
Total No. 364 506  
 
 
0.24 
89 545  
 
 
0.55 
453 1051  
 
 
0.03 
Sedentary 7.4% 4.5% 5.6% 10.3% 7.1% 7.5% 
Moderate 59.1% 62.2% 76.4% 73.2% 62.4% 67.9% 
Very active 33.5% 33.2% 18.0% 16.5% 30.5% 24.5% 
Parents 
affected 
Total No. 373 514  
 
 
 
0.79 
89 546  
 
 
 
0.71 
462 1060  
 
 
 
0.68 
None 56.0% 53.1% 57.3% 57.1% 56.3% 55.2% 
Father 15.0% 15.8% 16.9% 13.0% 15.4% 14.3% 
Mother 19.6% 20.0% 16.9% 18.3% 19.0% 19.1% 
Both 9.4% 11.1% 9.0% 11.5% 9.3% 11.3% 
Data values written as percent
 Table 3. Clinical Conditions in MetS and Non-MetS Categories among Asian Indian Diabetic Subjects 
Clinical 
Conditions 
Male 
 
P value 
Female 
 
P value 
Total 
 
P value 
Non-MetS 
N=373 
MetS 
N=514 
Non-MetS 
N=89 
MetS 
N=546 
Non-MetS 
N=462 
MetS 
N=1060 
CVD 27.1 30 
 
20.2 20.7 0.92 25.8 25.2 0.82 
Hypertension 33.8 77.6 <0.0001 16.9 71.8 <0.0001 30.5 74.6 <0.0001 
Retinopathies 34.3 35.2 0.78 33.7 36.6 0.59 34.2 36 0.51 
Cataract 16.9 17.5 0.81 14.6 18.1 0.42 16.5 17.8 0.51 
Neuropathies 42.1 36.6 0.1 49.4 52.6 0.58 43.5 44.8 0.64 
Nephropathies 3.2 6.8 0.02 2.3 4.6 0.31 3 5.7 0.03 
Diabetic Foot 4 5.3 0.39 3.4 2.6 0.66 3.9 3.9 0.98 
Skin/UTI 
infection 
12.9 18.3 0.03 21.3 20.1 0.79 14.5 19.2 0.03 
Stroke 2.7 4.1 0.26 2.2 3.1 0.66 2.6 3.6 0.32 
Data values written as percent  
Table 4. Regression analysis for having MetS among Asian Indian Diabetic subjects 
Parameters B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Upper Lower 
SEX -7.832 2.395 10.691 1 .001 .000 .000 .043 
Age .024 .021 1.343 1 .247 1.025 .983 1.068 
Family history of T2DM   .628 3 .890    
Father affected -.101 .301 .113 1 .736 .904 .501 1.629 
Mother affected .148 .270 .298 1 .585 1.159 .682 1.969 
Both Parents affected .120 .345 .120 1 .729 1.127 .573 2.217 
BMI -.386 .260 2.205 1 .138 .680 .408 1.131 
WC  .638 .187 11.598 1 .001 1.893 1.311 2.734 
Hip -.051 .068 .567 1 .451 .950 .831 1.086 
WHR -.190 .749 .064 1 .800 .827 .191 3.588 
SBP -.003 .006 .349 1 .555 .997 .985 1.008 
DBP .006 .011 .317 1 .573 1.006 .985 1.027 
Body fat% -.234 .135 2.998 1 .083 .791 .607 1.031 
Physical  Activity   2.854 3 .415    
Moderately active .920 .804 1.309 1 .253 2.509 .519 12.133 
Very active 1.005 .711 1.994 1 .158 2.731 .677 11.012 
Hypertension 3.582 .275 170.122 1 .000 35.949 20.985 61.582 
Glucose .003 .002 3.915 1 .048 1.003 1.000 1.006 
Total Cholesterol .158 .756 .044 1 .834 1.171 .266 5.151 
Triglycerides -.396 .765 .267 1 .605 .673 .150 3.019 
HDL-Cholesterol -.299 .756 .156 1 .692 .741 .168 3.265 
LDL-Cholesterol -.156 .756 .043 1 .836 .855 .194 3.762 
VLDL-Cholesterol 1.921 3.876 .246 1 .620 6.830 .003 13601.8 
Constant 10.607 12.617 .707 1 .400 40431.5   
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; WC, Waist Circumference; WHR, 
Waist Hip Ratio; BMI, Body Mass Index; HDL, High Density Lipoprotein; LDL, Low Density 
Lipoprotein; VLDL, Very Low Density Lipoprotein  
Table 5. Logistic Regression for CVD prediction among Asian Indian Diabetic Subjects  
Parameter B S.E. Wald df Sig. Exp(B) 95% CI for EXP(B) 
Lower Upper 
MetS ATP-III 
Classification 
1.234 0.492 6.293 1 0.012 3.436 1.310 9.014 
Sex 1.033 1.578 .428 1 .513 2.810 .127 61.976 
Age -.019 .026 .569 1 .451 .981 .932 1.032 
Parents affected   7.317 3 .062    
Father affected -.570 .241 5.585 1 .018 .566 .353 .907 
Mother affected .009 .191 .002 1 .964 1.009 .693 1.467 
Both parents affected -.394 .275 2.056 1 .152 .674 .394 1.155 
Age range   8.645 4 .071    
40-49 yrs .724 .618 1.373 1 .241 2.063 .615 6.924 
50-59 yrs 1.406 .700 4.037 1 .045 4.079 1.035 16.076 
60-69 yrs 1.987 .848 5.484 1 .019 7.292 1.383 38.463 
>70 2.171 1.048 4.290 1 .038 8.766 1.124 68.390 
BMI .368 .159 5.369 1 .021 1.445 1.058 1.974 
WC (inch) .109 .174 .392 1 .531 1.115 .793 1.569 
Hip (inch) -.129 .128 1.022 1 .312 .879 .684 1.129 
WHR -1.011 4.794 .044 1 .833 .364 .000 4381.196 
SBP -.014 .004 10.429 1 .001 .987 .978 .995 
DBP .003 .007 .126 1 .722 1.003 .988 1.017 
Body fat% .046 .091 .260 1 .610 1.047 .877 1.251 
Physical activity   10.346 3 .016    
Moderately active -3.247 1.113 8.504 1 .004 .039 .004 .345 
Very active -3.200 1.083 8.736 1 .003 .041 .005 .340 
Hypertension 1.150 .228 25.386 1 .000 3.158 2.019 4.941 
Glucose  -.001 .001 .523 1 .470 .999 .997 1.001 
Total Cholesterol  -.025 .538 .002 1 .963 .975 .339 2.802 
Triglycerides .191 .648 .087 1 .768 1.210 .340 4.308 
HDL-Cholesterol .014 .539 .001 1 .979 1.014 .353 2.915 
LDL-Cholesterol .014 .538 .001 1 .979 1.015 .353 2.915 
VLDL-Cholesterol -.939 3.337 .079 1 .778 .391 .001 270.424 
MetS Risk Factors   1.570 4 .814    
MetS-Risk Factors (2) -.205 .374 .299 1 .584 .815 .391 1.697 
MetS-Risk Factors (3) -.335 .406 .680 1 .410 .716 .323 1.586 
MetS-Risk Factors (4) -.163 .484 .114 1 .735 .849 .329 2.191 
MetS-Risk Factors (5) -.324 .585 .308 1 .579 .723 .230 2.274 
Constant -16.219 9.309 3.036 1 .081 .000   
 
